Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Rectal Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia 2Hodgkin Disease 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Papillomavirus Infections 1Oropharyngeal Neoplasms 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Colonic Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Anus Neoplasms 1Adenocarcinoma, Mucinous 1

Interventions

pembrolizumab 91Carboplatin 73Pemetrexed 58Nivolumab 50Docetaxel 47Cisplatin 47Paclitaxel 46Erlotinib Hydrochloride 37Radiotherapy 30Gemcitabine 27osimertinib 23Cetuximab 23Bevacizumab 21Ipilimumab 18Radiosurgery 14130-nm albumin-bound paclitaxel 14Taxes 13Gefitinib 13Cyclophosphamide 13avelumab 12atezolizumab 12durvalumab 11Albumin-Bound Paclitaxel 11cemiplimab 9Radiation 8Drug Therapy 8alectinib 7Injections 7Etoposide 7trametinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Non-Small-Cell Lung × Diphenhydramine × Clear all
NCT01455389 2022-03-02

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Genprex, Inc.

Phase 1/2 Terminated
25 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡